The neddylation inhibitor, pevonedistat (MLN4924), has been shown to inhibit CRL4-DCAF1 activity in Merlin-mutant mesothelioma and schwannoma, in order to activate the Hippo pathway and suppress growth [17]. This evidence concerns the gene IL17RB and schwannoma.